FR14C0039I1 - Formulation d'aripiprazole injectable sterile a liberation controlee et procede - Google Patents

Formulation d'aripiprazole injectable sterile a liberation controlee et procede

Info

Publication number: FR14C0039I1
Authority: FR; France
Prior art keywords: controlled release; sterile injectable; aripiprazole formulation; release sterile; injectable aripiprazole
Prior art date: 2003-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0039C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Otsuka Pharmaceutical Co Ltd

Original Assignee

Otsuka Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-23

Filing date

2014-05-13

Publication date

2014-06-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-13 Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd

2014-06-27 Publication of FR14C0039I1 publication Critical patent/FR14C0039I1/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

FR14C0039C 2003-10-23 2014-05-13 Formulation d'aripiprazole injectable sterile a liberation controlee et procede Active FR14C0039I1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51361803P	2003-10-23	2003-10-23
PCT/US2004/034367 WO2005041937A2 (fr)	2003-10-23	2004-10-18	Formulation d'aripiprazole injectable sterile a liberation controlee et procede

Publications (1)

Publication Number	Publication Date
FR14C0039I1 true FR14C0039I1 (fr)	2014-06-27

Family

ID=34549292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0039C Active FR14C0039I1 (fr)	2003-10-23	2014-05-13	Formulation d'aripiprazole injectable sterile a liberation controlee et procede

Country Status (32)

Country	Link
US (12)	US7807680B2 (fr)
EP (1)	EP1675573B2 (fr)
JP (2)	JP4836797B2 (fr)
KR (1)	KR100931784B1 (fr)
CN (1)	CN1870980B (fr)
AR (2)	AR046141A1 (fr)
AT (1)	ATE411797T2 (fr)
AU (1)	AU2004285448C1 (fr)
BR (1)	BRPI0415531B8 (fr)
CA (1)	CA2543242C (fr)
CO (1)	CO5690539A2 (fr)
CY (2)	CY1109040T1 (fr)
DE (1)	DE602004017342D1 (fr)
DK (1)	DK1675573T4 (fr)
EC (2)	ECSP066512A (fr)
ES (1)	ES2315721T5 (fr)
FR (1)	FR14C0039I1 (fr)
GE (1)	GEP20115205B (fr)
IL (1)	IL175072A (fr)
LU (1)	LU92427I2 (fr)
MX (1)	MXPA06004489A (fr)
MY (1)	MY146093A (fr)
NO (2)	NO334919B1 (fr)
NZ (1)	NZ546063A (fr)
PE (1)	PE20050811A1 (fr)
PL (1)	PL1675573T4 (fr)
PT (1)	PT1675573E (fr)
SI (1)	SI1675573T2 (fr)
TW (2)	TWI383810B (fr)
UA (1)	UA82561C2 (fr)
WO (1)	WO2005041937A2 (fr)
ZA (1)	ZA200602347B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
CA2543242C (fr)	2003-10-23	2015-04-14	Otsuka Pharmaceutical Co., Ltd.	Formulation d'aripiprazole lyophilisee sterile a liberation controlee etformulation injectable de celle-ci
EP1812397A1 (fr) *	2004-11-18	2007-08-01	Synthon B.V.	Procédé de synthèse d'aripiprazole cristallin
EP1933814A2 (fr) *	2005-09-15	2008-06-25	Elan Pharma International Limited	Formulations aripiprazoliques nanoparticulaires
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
EP1808164B2 (fr)	2006-01-05	2018-07-04	Teva Pharmaceutical Industries Ltd	Méthode de granulation humide pour préparer des compositions pharmaceutiques d'aripiprazole
WO2007081367A1 (fr) *	2006-01-05	2007-07-19	Teva Pharmaceutical Industries Ltd.	Formulations seches d'aripiprazole
TR200604349A2 (tr) *	2006-08-15	2008-03-21	NOBEL İLAÇ SANAYii VE TiCARET A.Ş.	Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) *	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
ES2529746T3 (es) *	2007-06-25	2015-02-25	Otsuka Pharmaceutical Co., Ltd.	Microesferas con una estructura de núcleo/cáscara
PT2170279T (pt) *	2007-07-31	2018-04-06	Otsuka Pharma Co Ltd	Métodos para produção de suspensão de aripiprazole e formulação liofilizada
CA2763456C (fr)	2009-05-27	2017-10-24	Alkermes Pharma Ireland Limited	Reduction de l'agregation a l'origine de paillettes dans des compositions a base d'un principe actif nanoparticulaire
KR101125210B1 (ko) *	2009-09-11	2012-03-19	주식회사 대웅제약	아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN103284968B (zh) *	2010-04-13	2015-11-18	齐鲁制药有限公司	一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
IL206739A (en) *	2010-06-30	2016-06-30	David Segal	An injectable drug containing silitol as an active substance
PH12012502076A1 (en)	2010-08-24	2013-02-04	Otsuka Pharma Co Ltd	Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9469630B2 (en)	2010-10-18	2016-10-18	Sumitomo Dainippon Pharma Co., Ltd.	Sustained-release formulation for injection
US9757374B2 (en) *	2010-10-28	2017-09-12	Aequus Pharmaceuticals Inc.	Aripiprazole compositions and methods for its transdermal delivery
WO2012058091A2 (fr) *	2010-10-28	2012-05-03	Alpha To Omega Pharmaceutical Consultants, Inc.	Compositions d'aripiprazole et méthodes pour leur administration transdermique
AR083884A1 (es)	2010-11-16	2013-03-27	Otsuka Pharma Co Ltd	Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) *	2010-12-14	2016-09-28	江苏豪森药业集团有限公司	一种持续释放的注射制剂及其制备方法和用途
CA2910333C (fr) *	2011-01-24	2017-03-07	Otsuka Pharmaceutical Co., Ltd.	Dispositif medical contenant une composition de gateau comprenant de l'aripiprazole comme ingredient actif, et composition de gateau comprenant de l'aripiprazole comme ingredient actif
EP3156056B1 (fr)	2011-03-18	2023-12-06	Alkermes Pharma Ireland Limited	Compositions pharmaceutiques comprenant des esters de sorbitan
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
US9241876B2 (en) *	2011-06-27	2016-01-26	Shanghai Zhongxi Pharmaceutical Corporation	Aripiprazole medicament formulation and preparation method therefor
CN102850268B (zh) *	2011-06-27	2015-07-15	上海中西制药有限公司	阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
CA2867137C (fr)	2012-03-19	2020-12-08	Alkermes Pharma Ireland Limited	Compositions pharmaceutiques renfermant des promedicaments d'aripiprazole et d'alcool benzylique
CA2867123C (fr)	2012-03-19	2021-02-16	Alkermes Pharma Ireland Limited	Compositions pharmaceutiques renfermant des agents antipsychotiques non hydrosolubles et des esters glycerol
JP6471089B2 (ja) *	2012-03-19	2019-02-13	アルカームスファーマアイルランドリミテッド	脂肪酸エステルを含む医薬組成物
JOP20200109A1 (ar) *	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
AR090775A1 (es)	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
TWI562991B (en)	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN104736566A (zh)	2012-08-21	2015-06-24	奥索临床诊断有限公司	帕潘立酮半抗原的抗体及其用途
PL2888286T3 (pl) *	2012-08-21	2018-07-31	Janssen Pharmaceutica Nv	Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888593T3 (pl) *	2012-08-21	2019-02-28	Janssen Pharmaceutica Nv	Przeciwciała przeciwko rysperydonowi i ich zastosowanie
CA2882615C (fr)	2012-08-21	2019-07-09	Ortho-Clinical Diagnostics, Inc.	Anticorps diriges contre la quetiapine et leur utilisation
JP6374387B2 (ja)	2012-08-21	2018-08-15	ヤンセンファーマシューティカエヌ．ベー．	リスペリドンハプテンへの抗体及びその使用
CN108640996A (zh)	2012-08-21	2018-10-12	詹森药业有限公司	帕潘立酮的抗体及其用途
CA2885196C (fr)	2012-09-19	2021-06-22	Alkermes Pharma Ireland Limited	Compositions pharmaceutiques ayant une plus grande stabilite au stockage
KR20170052704A (ko) *	2013-04-30	2017-05-12	오쓰까 세이야꾸 가부시키가이샤	아리피프라졸을 포함하는 경구 고형 제제 및 아리피프라졸을 포함하는 경구 고형 제제의 제조방법
AR096131A1 (es)	2013-04-30	2015-12-09	Otsuka Pharma Co Ltd	Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP6524110B2 (ja) *	2014-03-20	2019-06-05	アルカームスファーマアイルランドリミテッド	注射速度が増大したアリピプラゾール調合物
US10016415B2 (en)	2014-08-18	2018-07-10	Alkermes Pharma Ireland Limited	Aripiprazole prodrug compositions
HRP20211271T1 (hr) *	2014-08-18	2022-01-07	Alkermes Pharma Ireland Limited	Pripravci aripiprazolskog predlijeka
MA40480B1 (fr) *	2014-08-25	2021-08-31	Alkermes Pharma Ireland Ltd	Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
WO2016189504A1 (fr) *	2015-05-28	2016-12-01	Leiutis Pharmaceuticals Pvt Ltd	Compositions non lyophilisée d'aripiprazole et procédés de préparation de celles-ci
TWI584823B (zh) *	2015-08-31	2017-06-01	諾瑞特國際藥業股份有限公司	具有延長的保存期限的阿立哌唑可注射懸浮液製劑
CN106474058B (zh) *	2015-08-31	2020-01-07	南京诺瑞特医药科技有限公司	具有延长的保质期的阿立哌唑可注射悬浮液制剂
JP6504019B2 (ja) *	2015-10-27	2019-04-24	豊田合成株式会社	発光装置
MA44067A (fr)	2015-12-17	2018-10-24	Janssen Pharmaceutica Nv	Anticorps dirigés contre la quétiapine et utilisation associée
CA3008809A1 (fr)	2015-12-17	2017-06-22	Janssen Pharmaceutica Nv	Anticorps anti-risperidone et leur utilisation
CN105663057A (zh) *	2015-12-30	2016-06-15	中国药科大学	阿立哌唑长效混悬剂及其制备方法
US20190160002A1 (en) *	2016-07-28	2019-05-30	Mylan Laboratories Limited	Process for preparing sterile aripiprazole formulation
JP7384812B2 (ja)	2018-03-05	2023-11-21	アルカームスファーマアイルランドリミテッド	アリピプラゾール投与戦略
CN108498456B (zh)	2018-05-16	2021-01-01	丽珠医药集团股份有限公司	一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) *	2019-08-06	2021-10-22	深圳市泛谷药业股份有限公司	一种阿立哌唑长效注射制剂及其制备方法
KR102486564B1 (ko) *	2019-08-23	2023-01-19	주식회사 대웅테라퓨틱스	니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
WO2021140424A1 (fr) *	2020-01-06	2021-07-15	Shilpa Medicare Limited	Suspension injectable à libération prolongée de fingolimod
WO2021199076A1 (fr)	2020-03-30	2021-10-07	Cipla Limited	Formulation d'aripiprazole injectable
MX2022012353A (es) *	2020-04-01	2022-10-31	Otsuka Pharma Co Ltd	Metodos para el inicio de la dosis de los tratamientos con aripiprazol.
KR102606504B1 (ko) *	2020-04-10	2023-11-29	주식회사 대웅테라퓨틱스	니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
WO2021233402A1 (fr) *	2020-05-21	2021-11-25	江苏先声药业有限公司	Composition pharmaceutique contenant du brexpiprazole et son procédé de préparation
KR102785446B1 (ko) *	2020-09-09	2025-03-25	주식회사 대웅테라퓨틱스	니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
CN112656761B (zh) *	2020-12-30	2023-09-08	河南合智医药科技有限公司	一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法
EP4043008A1 (fr)	2021-02-15	2022-08-17	Warszawskie Zaklady Farmaceutyczne Polfa S.A.	Procédé de préparation d'une composition pharmaceutique comprenant de l'aripiprazole
HUP2100259A1 (hu)	2021-07-07	2023-01-28	Richter Gedeon Nyrt	Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115554253B (zh) *	2022-10-14	2024-03-29	浙江圣兆药物科技股份有限公司	一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
GR1010656B (el) *	2023-03-23	2024-03-21	Φαρματεν Α.Β.Ε.Ε.,	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1010624B (el) *	2023-03-23	2024-01-30	Φαρματεν Α.Β.Ε.Ε.,	Φαρμακευτικο σκευασμα που περιλαμβανει αριπιπραζολη και μεθοδος για την παρασκευη αυτου
WO2024225441A1 (fr)	2023-04-26	2024-10-31	Otsuka Pharmaceutical Co., Ltd.	Initiation de dose pour le traitement de la schizophrénie ou du trouble bipolaire i avec de l'aripiprazole

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB209551A (en)	1922-11-20	1924-01-17	William Mortimer Melmore	Improvements in or relating to petrol and other cans
US4038389A (en)	1975-05-07	1977-07-26	The Upjohn Company	Medroxyprogesterone acetate compositions
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
CA1209477A (fr)	1981-03-26	1986-08-12	Bruce E. Haeger	Compose comprenant une preparation lyophilisee de derive de la penicilline
JPS5832899A (ja)	1981-08-18	1983-02-25	Takeda Chem Ind Ltd	オキセンドロン水性懸濁剤
US4352811A (en)	1981-11-12	1982-10-05	Hoechst-Roussel Pharmaceuticals Inc.	3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) *	1983-05-03	1988-05-31	Kit Medidont Ltd	Method and instrument for measuring moisture
KR850004274A (ko)	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4804663A (en)	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JPH03212852A (ja)	1990-01-18	1991-09-18	Hitachi Electron Eng Co Ltd	記録媒体カートリッジ搬送装置における送り機構
FR2663223B1 (fr)	1990-06-14	1994-12-02	Af Aplicaciones Far Lab	Forme galenique parenterale.
JP3282731B2 (ja)	1990-06-15	2002-05-20	メルクエンドカムパニーインコーポレーテッド	結晶の構造および大きさを改良する結晶化方法
IT1244880B (it)	1990-12-11	1994-09-12	Torre A Farmaceutici	Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en)	1992-06-01	2001-02-27	The University Of Melbourne	Equine herpesvirus glycoproteins
TW376319B (en)	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
SK282231B6 (sk)	1993-11-19	2001-12-03	Janssen Pharmaceutica N. V.	Farmaceutický prostriedok na liečenie psychotických porúch
DE69530196T2 (de)	1994-06-02	2003-11-20	Elan Drug Delivery Ltd	Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
RU2082401C1 (ru)	1994-08-18	1997-06-27	Фармацевтическое акционерное общество "Ферейн"	Способ получения лекарственной формы комбинированного препарата
US6165442A (en)	1996-02-19	2000-12-26	Nycomed Imaging As	Thermally stabilized ultrasound contrast agent
TW487572B (en)	1996-05-20	2002-05-21	Janssen Pharmaceutica Nv	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ATE252891T1 (de)	1996-08-26	2003-11-15	Transgene Sa	Kationische lipid-nukleinsäure komplexe
US6297231B1 (en)	1996-10-28	2001-10-02	Merck & Co., Inc.	Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) *	1997-03-18	1997-05-07	Anglia Research Foundation	Stable particle in liquid formulations
GB9718986D0 (en)	1997-09-09	1997-11-12	Danbiosyst Uk	Controlled release microsphere delivery system
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2000006124A2 (fr)	1998-07-30	2000-02-10	Point Biomedical Corporation	Nouvel excipient utile pour lyophiliser des suspensions aqueuses de microparticules
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en)	1998-12-16	2002-09-24	Aventis Pharmaceuticals, Inc.	Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en)	1999-03-08	2001-07-31	Klan Pharma International Ltd.	Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2382921A1 (fr)	1999-12-09	2001-06-14	Syngenta Participations Ag	Pyrazolecarboxamide and pyrazolethioamide en tant que fongicide
JP2001187735A (ja) *	2000-01-05	2001-07-10	Towa Yakuhin Kk	安定なニコランジル含有粉末の製造法
US6559128B1 (en)	2000-01-21	2003-05-06	Northwestern University	Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru)	2000-01-27	2001-06-27	Кобатов Алексей Иванович	Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en)	2000-02-10	2001-08-20	Alkermes Controlled Therapeutics, Inc.	Method of preparing a sustained release composition
JP2003528850A (ja)	2000-03-27	2003-09-30	ザ・スクリプス・リサーチ・インステイチユート	血管形成および腫瘍成長の阻害
EP1187602A4 (fr)	2000-04-18	2004-09-15	Peptron Inc	Composition pharmaceutique injectable a liberation durable et procedes de preparation de celle-ci
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) *	2001-02-16	2002-08-28	Towa Yakuhin Kk	全身投与用アルガトロバン注射液
MY129350A (en)	2001-04-25	2007-03-30	Bristol Myers Squibb Co	Aripiprazole oral solution
JP2003063965A (ja) *	2001-06-13	2003-03-05	Otsuka Pharmaceut Factory Inc	注射用シロスタゾール水性製剤
US6884768B2 (en)	2001-06-14	2005-04-26	Otsuka Pharmaceutical Co., Ltd.	Medicinal compositions
DK1429734T3 (da)	2001-09-21	2008-05-13	Egalet As	Faste dispersioner af carvedilol til kontrolleret afgivelse
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MY138669A (en) *	2001-09-25	2009-07-31	Otsuka Pharma Co Ltd	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
ITMI20020808A1 (it)	2002-04-17	2003-10-17	Chiesi Farma Spa	Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
WO2004006959A1 (fr) *	2002-07-16	2004-01-22	Elan Pharma International, Ltd	Compositions pour doses liquides d'agents actifs nanoparticulaires stables
CN100335047C (zh) *	2002-08-20	2007-09-05	布里斯托尔-迈尔斯斯奎布公司	阿立哌唑复合制剂和方法
WO2004064752A2 (fr) *	2003-01-22	2004-08-05	Alkermes Controlled Therapeutics, Inc.	Procede de preparation de microparticules a liberation prolongee
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
US6987111B2 (en)	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
CA2543242C (fr)	2003-10-23	2015-04-14	Otsuka Pharmaceutical Co., Ltd.	Formulation d'aripiprazole lyophilisee sterile a liberation controlee etformulation injectable de celle-ci
EP1677738A2 (fr)	2003-10-31	2006-07-12	Point Biomedical Corporation	Compositions de microspheres reconstitutables utilisees en tant qu'agents de contraste ultrasonores

2004
- 2004-10-18 CA CA2543242A patent/CA2543242C/fr not_active Expired - Lifetime
- 2004-10-18 BR BRPI0415531A patent/BRPI0415531B8/pt not_active IP Right Cessation
- 2004-10-18 EP EP04795514A patent/EP1675573B2/fr not_active Expired - Lifetime
- 2004-10-18 WO PCT/US2004/034367 patent/WO2005041937A2/fr not_active Ceased
- 2004-10-18 SI SI200430966T patent/SI1675573T2/sl unknown
- 2004-10-18 AT AT04795514T patent/ATE411797T2/de active
- 2004-10-18 NZ NZ546063A patent/NZ546063A/en not_active IP Right Cessation
- 2004-10-18 JP JP2006536693A patent/JP4836797B2/ja not_active Expired - Lifetime
- 2004-10-18 AU AU2004285448A patent/AU2004285448C1/en active Active
- 2004-10-18 PT PT04795514T patent/PT1675573E/pt unknown
- 2004-10-18 CN CN2004800308144A patent/CN1870980B/zh not_active Expired - Lifetime
- 2004-10-18 UA UAA200604046A patent/UA82561C2/uk unknown
- 2004-10-18 DE DE602004017342T patent/DE602004017342D1/de not_active Expired - Lifetime
- 2004-10-18 ES ES04795514T patent/ES2315721T5/es not_active Expired - Lifetime
- 2004-10-18 ZA ZA200602347A patent/ZA200602347B/en unknown
- 2004-10-18 GE GEAP20049360A patent/GEP20115205B/en unknown
- 2004-10-18 MX MXPA06004489A patent/MXPA06004489A/es active IP Right Grant
- 2004-10-18 PL PL04795514T patent/PL1675573T4/pl unknown
- 2004-10-18 DK DK04795514.1T patent/DK1675573T4/da active
- 2004-10-18 KR KR1020067007890A patent/KR100931784B1/ko not_active Expired - Lifetime
- 2004-10-19 US US10/968,482 patent/US7807680B2/en not_active Expired - Lifetime
- 2004-10-20 TW TW093131836A patent/TWI383810B/zh not_active IP Right Cessation
- 2004-10-20 TW TW100136057A patent/TWI421101B/zh not_active IP Right Cessation
- 2004-10-22 MY MYPI20044358A patent/MY146093A/en unknown
- 2004-10-22 AR ARP040103849A patent/AR046141A1/es not_active Application Discontinuation
- 2004-10-25 PE PE2004001021A patent/PE20050811A1/es active IP Right Grant
2006
- 2006-04-18 EC EC2006006512A patent/ECSP066512A/es unknown
- 2006-04-19 CO CO06036842A patent/CO5690539A2/es active IP Right Grant
- 2006-04-20 IL IL175072A patent/IL175072A/en not_active IP Right Cessation
- 2006-05-22 NO NO20062319A patent/NO334919B1/no active Protection Beyond IP Right Term
2007
- 2007-08-17 US US11/889,935 patent/US20080221121A1/en not_active Abandoned
- 2007-10-31 US US11/979,144 patent/US20080112985A1/en not_active Abandoned
- 2007-10-31 US US11/979,145 patent/US8722679B2/en active Active
- 2007-10-31 US US11/979,149 patent/US8030313B2/en active Active
2008
- 2008-12-31 CY CY20081101518T patent/CY1109040T1/el unknown
2011
- 2011-01-14 JP JP2011006037A patent/JP5372032B2/ja not_active Expired - Lifetime
- 2011-12-28 US US13/338,827 patent/US8952013B2/en active Active
2012
- 2012-01-20 EC EC2012006512A patent/ECSP12006512A/es unknown
2013
- 2013-09-19 US US14/031,571 patent/US20140018369A1/en not_active Abandoned
2014
- 2014-04-11 LU LU92427C patent/LU92427I2/fr unknown
- 2014-05-13 CY CY2014021C patent/CY2014021I2/el unknown
- 2014-05-13 FR FR14C0039C patent/FR14C0039I1/fr active Active
- 2014-10-06 US US14/507,303 patent/US9763935B2/en not_active Expired - Fee Related
- 2014-10-27 NO NO2014027C patent/NO2014027I1/no not_active IP Right Cessation
2016
- 2016-10-21 AR ARP160103230A patent/AR106449A2/es not_active Application Discontinuation
2017
- 2017-08-18 US US15/680,291 patent/US20170348308A1/en not_active Abandoned
2019
- 2019-10-30 US US16/668,008 patent/US20200061057A1/en not_active Abandoned
2021
- 2021-07-16 US US17/377,898 patent/US20210338663A1/en not_active Abandoned
2024
- 2024-04-10 US US18/631,828 patent/US20240261280A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL1675573T5 (pl)	2012-10-31
NO20062319L (no)	2006-07-21
SI1675573T1 (sl)	2009-02-28
CO5690539A2 (es)	2006-10-31
WO2005041937A3 (fr)	2006-04-06
US20050148597A1 (en)	2005-07-07
DE602004017342D1 (de)	2008-12-04
KR20060118450A (ko)	2006-11-23
TWI421101B (zh)	2014-01-01
US9763935B2 (en)	2017-09-19
ECSP066512A (es)	2006-10-10
DK1675573T4 (da)	2012-08-06
CY2014021I2 (el)	2017-03-15
UA82561C2 (uk)	2008-04-25
US20080112985A1 (en)	2008-05-15
AR046141A1 (es)	2005-11-23
KR100931784B1 (ko)	2009-12-14
LU92427I2 (fr)	2014-06-11
JP2007509148A (ja)	2007-04-12
TW200524638A (en)	2005-08-01
NZ546063A (en)	2009-05-31
US20140018369A1 (en)	2014-01-16
NO334919B1 (no)	2014-07-14
PL1675573T4 (pl)	2016-04-29
ES2315721T5 (es)	2012-08-24
EP1675573A2 (fr)	2006-07-05
US20120100190A1 (en)	2012-04-26
ES2315721T3 (es)	2009-04-01
RU2342927C2 (ru)	2009-01-10
AU2004285448C1 (en)	2021-08-19
CY1109040T1 (el)	2014-07-02
CA2543242C (fr)	2015-04-14
ES2315721T9 (es)	2015-11-05
US20080112986A1 (en)	2008-05-15
BRPI0415531B8 (pt)	2021-05-25
RU2006109111A (ru)	2007-09-27
US8722679B2 (en)	2014-05-13
US20200061057A1 (en)	2020-02-27
PL1675573T3 (pl)	2009-04-30
EP1675573B2 (fr)	2012-06-13
PT1675573E (pt)	2008-12-30
AU2004285448A1 (en)	2005-05-12
DK1675573T3 (da)	2009-01-05
CY2014021I1 (el)	2014-07-02
US8030313B2 (en)	2011-10-04
GEP20115205B (en)	2011-04-26
US20240261280A1 (en)	2024-08-08
JP4836797B2 (ja)	2011-12-14
ATE411797T2 (de)	2008-11-15
NO2014027I1 (no)	2014-11-10
HK1095266A1 (zh)	2007-05-04
MXPA06004489A (es)	2006-06-20
PE20050811A1 (es)	2005-09-25
WO2005041937A2 (fr)	2005-05-12
CA2543242A1 (fr)	2005-05-12
US7807680B2 (en)	2010-10-05
MY146093A (en)	2012-06-29
CN1870980B (zh)	2010-06-23
BRPI0415531A (pt)	2006-12-26
NO2014027I2 (no)	2014-10-27
AR106449A2 (es)	2018-01-17
CN1870980A (zh)	2006-11-29
US20080107745A1 (en)	2008-05-08
US20210338663A1 (en)	2021-11-04
IL175072A (en)	2015-06-30
JP2011102316A (ja)	2011-05-26
ZA200602347B (en)	2007-09-26
US20170348308A1 (en)	2017-12-07
JP5372032B2 (ja)	2013-12-18
LU92427I9 (fr)	2019-01-17
US20150024056A1 (en)	2015-01-22
BRPI0415531B1 (pt)	2019-07-30
TWI383810B (zh)	2013-02-01
ECSP12006512A (es)	2012-02-29
US8952013B2 (en)	2015-02-10
IL175072A0 (en)	2006-08-20
AU2004285448B2 (en)	2009-06-11
SI1675573T2 (sl)	2012-08-31
TW201204413A (en)	2012-02-01
US20080221121A1 (en)	2008-09-11
EP1675573B1 (fr)	2008-10-22

Publication	Publication Date	Title
FR14C0039I1 (fr)	2014-06-27	Formulation d'aripiprazole injectable sterile a liberation controlee et procede
DE60329729D1 (de)	2009-12-03	Implantierbare Vorrichtung zur Arzneimittelverabreichung
FR2856579B1 (fr)	2006-03-17	Materiel d'osteosynthese vertebrale et procede de fabrication d'un organe d'ancrage osseux que comprend ce materiel
DE60036753D1 (de)	2007-11-29	Automatische Analysevorrichtung, sowie Verwaltungsvorrichtung und Rechnerprogramprodukt zur Verwaltung davon
DE602004017934D1 (de)	2009-01-08	Gerät zum Einfügen chirurgischer Befestigungselemente
FI20030647L (fi)	2004-10-30	Menetelmä ja laite ihmisen painon hallintaan
ATE464050T1 (de)	2010-04-15	Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
NL1024584A1 (nl)	2004-05-06	Werkwijze en inrichting voor medische interventieprocedureplanning.
AU2003209747A8 (en)	2003-10-13	Medical instrument for holding open an intervention site and a method for producing the same
AU2003209396A1 (en)	2003-10-13	Surgical site marking system
DE60233825D1 (de)	2009-11-05	BENZOATESÄURE-2-(a-HYDROXYPENTYL)ESTER UND DESSEN HERSTELLUNG UND VERWENDUNG
FR2866459B1 (fr)	2007-01-05	Procede d'activation d'un appareil medical
DE60124428D1 (de)	2006-12-21	Lüftungsvorrichtung und verfahren zu dessen herstellung
FR2846545B1 (fr)	2005-09-09	Implant d'osteosynthese intramedullaire
EP1683825A4 (fr)	2012-01-04	Film a haute resistance a l'humidite et procede d'elaboration
PL372710A1 (en)	2005-07-25	Device for locoregional anesthesia and method for making the cannula of said device
DE602004027730D1 (de)	2010-07-29	Medizinisches knochenprothesematerial und verfahren zu seiner herstellung
EP1538664A4 (fr)	2007-04-04	Agent d'attaque et procede d'attaque
DE602005023127D1 (de)	2010-10-07	Künstliche physiologische salzlösung und verfahren zu ihrer herstellung
EP1667028A4 (fr)	2008-10-29	Antememoire et procede de commande d'antememoire
EP1744782A4 (fr)	2011-02-16	Preparation a liberation prolongee destinee a l'administration orale d'un inhibiteur de la hmg-coa reductase et son procede de preparation
DE60321507D1 (de)	2008-07-24	Katheter zur künstlichen Befruchtung
EP1809307A4 (fr)	2012-08-01	Solution medicale et son procede de production et d'utilisation
ATE358470T1 (de)	2007-04-15	Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
FR2871832B1 (fr)	2007-12-21	Mecanisme de verrouillage et son procede d'actionnement